Alaunos Therapeutics Files 8-K/A Amendment

TL;DR

Alaunos Therapeutics filed an amendment to its 8-K, likely correcting or adding details to a prior filing.

AI Summary

Alaunos Therapeutics, Inc. filed an amendment (8-K/A) on July 17, 2024, to a previous report dated July 16, 2024. This amendment pertains to "Other Events" and "Financial Statements and Exhibits." The company, formerly known as ZIOPHARM ONCOLOGY INC, is incorporated in Delaware and headquartered in Houston, TX.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to the information previously disclosed by Alaunos Therapeutics.

Risk Assessment

Risk Level: low — This is a procedural amendment to a previous filing, not indicating new material events or financial distress.

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Registrant
• ZIOPHARM ONCOLOGY INC (company) — Former company name
• July 16, 2024 (date) — Date of earliest event reported
• July 17, 2024 (date) — Filing date of the amendment
• Houston, TX (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar

Filing Documents

• tcrt-20240716.htm (8-K/A) — 48KB
• tcrt-ex3_1.htm (EX-3.1) — 44KB
• 0000950170-24-084023.txt ( ) — 223KB
• tcrt-20240716.xsd (EX-101.SCH) — 31KB
• tcrt-20240716_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On June 26, 2024, the Board of Directors of Alaunos Therapeutics, Inc. (the "Company") approved the filing with the Secretary of State of the State of Delaware, to occur on July 16, 2024, of a Third Amended and Restated Certificate of Incorporation (the "Charter Amendment") in order to effect a reverse stock split of the Company's common stock at a ratio of 1-for-10 (the "Reverse Split"). The Charter Amendment provides that the Reverse Split will become effective on July 17, 2024 at 5:00 p.m. Eastern Time, at which time every 10 shares of the Company's issued and outstanding common stock will automatically be combined and converted into 1 share of common stock. Beginning with the opening of trading on Thursday, July 18, 2024, the Company's common stock will continue to trade on The Nasdaq Stock Market under the symbol "TCRT," but will trade on a split-adjusted basis under a new CUSIP number, 98973P309. The Charter Amendment effecting the Reverse Split was approved by the stockholders of the Company at the Company's Annual Meeting of Stockholders held on June 6, 2024. In connection with approving the Reverse Split, the Company's stockholders granted authority to the Board of Directors of the Company (the "Board") to determine in its sole discretion the exact ratio within the range of 1-for-5 to 1-for-15 at which to effectuate the Reverse Split. The Reverse Split was approved by the Board on June 26, 2023 and the ratio of 1-for-10 was also approved by the Board on June 26, 2024. Equiniti Trust Company ("Equiniti") is acting as the exchange agent for the Reverse Split. Equiniti will provide instructions to stockholders regarding the process for exchanging their pre-split shares for post-split shares. The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K an

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Third Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. 104 Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALAUNOS THERAPEUTICS, INC. By: /s/ Melinda Lackey Melinda Lackey Legal & Administration Date: July 16, 2024

View Full Filing

View this 8-K/A filing on SEC EDGAR